Transforming the treatment of
fibro-inflammatory diseases
Developer of first-in-class therapeutics targeting the IL-11 pathway
Our Focus
IL-11 signalling is a fundamentally important driver of fibrogenesis, organ dysfunction and inflammation across human fibrotic diseases.
Enleofen develops innovative, safe and highly effective therapeutics that address today’s biggest healthcare challenges.
Our Strategy
